One Comprehensive Universal Radiotherapy for Everyone (1-CURE)

SOL #: ARPA-H-SOL-26-147Solicitation

Overview

Buyer

Health And Human Services
National Institutes Of Health
ADVANCED RESEARCH PROJECTS AGENCY FOR HEALTH (ARPA-H)
Washington, DC, 20005, United States

Place of Performance

Place of performance not available

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

PSC

Health R&D Services; Health Care Services; Experimental Development (AN13)

Set Aside

No set aside specified

Timeline

1
Posted
Mar 12, 2026
2
Last Updated
May 1, 2026
3
Submission Deadline
May 23, 2026, 3:59 AM

Qualification Details

Fit reasons
  • NAICS alignment with historical contract wins in similar service areas.
  • Scope strongly matches core technical capabilities and delivery model.
Risks
  • Past performance thresholds may require one additional teaming partner.
  • Potential clarification needed on staffing minimums before bid/no-bid.
Next steps

Validate eligibility requirements, assign capture owner, and schedule partner outreach to confirm teaming strategy before submission planning.

Quick Summary

The Advanced Research Projects Agency for Health (ARPA-H) has issued an Innovative Solutions Opening (ISO) for the One Comprehensive Universal Radiotherapy for Everyone (1-CURE) program. This solicitation seeks revolutionary radiotherapy (RT) approaches to treat all cancers with a single, rapid, and low-cost method. ARPA-H anticipates awarding multiple Other Transaction (OT) Agreements. Full Proposals are due by May 22, 2026, at 11:59 PM ET.

Scope of Work

The 1-CURE program aims to integrate ultra-high dose rate (FLASH)-RT with multifunctional immunogenic smart radiotherapy biomaterials (SRBs) to significantly boost the abscopal effect, leading to the regression of both local and metastatic tumors with minimal toxicities. The ultimate goal is to achieve a universal curative treatment. Proposals must address two Technical Areas (TAs):

  • TA1: Immunogenic Nanoparticle SRBs: Develop multi-functional nanoparticle SRBs for tumor targeting, image guidance, and sustained immunoadjuvant delivery to enhance abscopal responses.
  • TA2: Abscopal Treatment Planning System (ATPS): Create an ATPS that integrates FLASH-RT and immunogenic SRBs to plan 1-CURE treatments, targeting over 90% abscopal responses with minimal toxicities.

Contract & Timeline

  • Contract Type: Multiple Other Transaction (OT) Agreements.
  • Period of Performance: 60 months, structured into three phases (Phase I: 18 months, Phase II: 18 months, Phase III: 24 months).
  • Set-Aside: None specified.
  • Full Proposals Due: May 22, 2026, 11:59 PM ET.
  • Published Date: May 1, 2026 (initial), revised May 4, 2026.

Eligibility & Submission Requirements

Eligible proposers include universities, non-profit organizations, small businesses, and other than small businesses. Federally Funded Research and Development Centers (FFRDCs) and other Government entities are prohibited from participating as prime or sub-performers. For-profit organizations not qualifying as small businesses are required to contribute a meaningful cost share. Proposers must have an active SAM.gov registration.

The submission process includes a mandatory Solution Summary (due April 15, 2026 - past due) followed by a Full Proposal for selected teams. Full Proposals must consist of four volumes:

  • Volume I: Technical and Management Proposal: Includes Executive Summary, Technical Plan, Management Plan, Capabilities, Commercialization Plan, Task Description Document (TDD), Target Product Profiles (TPP), Schedule and Milestones, and a Data Management and Sharing Plan (DMSP). Page limits apply to most sections.
  • Volume II: Cost Proposal: Requires an editable Excel Cost Proposal Spreadsheet (Appendix L) and supporting documentation, with no page limit.
  • Volume III: Administrative and Policy Requirements Submission: Includes disclosures on Organizational Conflict of Interest (OCI), Research Security, Intellectual Property (IP), Human Subjects Research (HSR), and Animal Subjects Research (ASR). Biographical Common Forms, Current and Pending Support, and Collaborators forms may be submitted during the negotiation phase.
  • Volume IV: Draft OT Response: A copy of the draft Other Transaction agreement with any proposed changes.

Evaluation Criteria

Proposals will be evaluated based on:

  1. Overall Scientific and Technical Merit
  2. Proposer's Capabilities and/or Related Experience
  3. Potential Contribution to Relevance to the ARPA-H Mission and User Experience
  4. Price/Cost

Additional Notes

Proposers are encouraged to monitor the 1-CURE Frequently Asked Questions (FAQ) page at https://arpa-h.gov/explore-funding/programs/1-cure/faqs for the latest information and updates. Details regarding a Proposers’ Day are available in a separate Special Notice, ARPA-H-SN-26-152.

People

Points of Contact

The 1-CURE TeamPRIMARY

Files

Files

Download
Download
Download
Download
Download
Download
Download
Download
Download
Download
Download
Download
Download
Download
Download
Download
Download

Versions

Version 5Viewing
Solicitation
Posted: May 1, 2026
Version 4
Solicitation
Posted: Apr 29, 2026
View
Version 3
Solicitation
Posted: Apr 16, 2026
View
Version 2
Solicitation
Posted: Apr 14, 2026
View
Version 1
Solicitation
Posted: Mar 12, 2026
View
One Comprehensive Universal Radiotherapy for Everyone (1-CURE) | GovScope